Cite
MLA Citation
C. Gousis et al.. “Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER+ MBC): The Guy's Cancer Centre Experience.” Clinical oncology, vol. 34, no. 4, 2022, pp. e178–. http://access.bl.uk/ark:/81055/vdc_100152634980.0x000032